Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLC
Tweet Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has withdrawn its European ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
